The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy

Atherosclerosis

Volumn 153, Issue 1, 2000, Pages 89-98

  Yamamoto, Akira ^a,i   Harada Shiba, Mariko ^a   Kawaguchi, Akito ^a   Oi, Keiko ^b   Kubo, Hitoshi ^b   Sakai, Soichi ^b   Mikami, Yoshikazu ^c   Imai, Tetsuya ^d   Ito, Toshiko ^e   Kato, Hiroshi ^e   Endo, Michinori ^f   Sato, Isamu ^g   Suzuki, Yasushi ^g   Hori, Hideshi ^h  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIZUOKA RED CROSS HOSPITAL   (Japan)

^d Iseikai Hospital   (Japan)

^e NISHI KOBE MEDICAL CENTER   (Japan)

^f Seisuikan Hospital   (Japan)

^g Saiseikai Niigata Second Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

ⁱ Health Care Facilities for the Aged   (Japan)

Author keywords

Atorvastatin; Cholesterol metabolism; Familial hypercholersterolemia (therapy); Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor; LDL aphersis; Serum cholestertol

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HOMOZYGOSITY; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MALE; PARESTHESIA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; BLOOD COMPONENT REMOVAL; FEMALE; HEPTANOIC ACIDS; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA, FAMILIAL; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, LDL; LYMPHOCYTES; MALE; MEVALONIC ACID; MIDDLE AGE; PYRROLES; RECEPTORS, LDL;

EID: 0033776766     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00373-7     Document Type: Article

References (45)

1. How effective is drug therapy in heterozygous familial hypercholesterolemia
2. Clinical features of familial hypercholesterolemia
3. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia
4. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia
5. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia
6. Plasmapheresis for prevention and regression of coronary atherosclerosis
7. Apheresis technology for prevention and regression of atherosclerosis: an overview
8. Assessment of long-term plasma exchange for familial hypercholesterolemia
9. LDL-apheresis: potential procedure for prevention and regression of atherosclerotic vascular lesion
10. Regression of carotid plaque during low density lipoprotein cholesterol elimination
11. Regression of valvular aortic stenosis due to homozygous familial hypercholesterolemia following plasmapheresis
12. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis
13. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia
14. Fifteen years experience with LDL-apheresis
15. Hypercholesterolemic valvulopathy: characteristic distribution of premature atherosclerosis in homozygous and heterozygous familial hypercholesterolemia
16. Siblings with normal LDL receptor activity and severe hypercholesterolemia
17. Therapeutic effect of ML-236B in primary hypercholesterolemia
18. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia
19. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study)
20. A multicenter, double blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
21. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors
22. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in minature pigs
23. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
24. Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vitro
25. Clinical efficacy of CI-981 (Atorvastatin) with heterozygous familial hypercholesterolemia
26. Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radial immunodiffusion assays
27. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences
28. Fundamental evaluation of measurement of lipoprotein(a) by Tint Elize Lp(a)
29. New micromethod for measuring cholesterol in plasma lipoprotein fractions
30. Rebound curve following LDL-apheresis reflects catabolic rate of plasma cholesterol and the synthetic rate of Lp(a)
31. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation
32. Measurement of mevalonic acid in plasma by GC-MS
33. A rapid flow cytometric assay for low-density lipoprotein receptors in human peripheral blood mononuclear cells
34. Receptor-mediated control of cholesterol metabolism
35. Treatment of homozygous familial hypercholesterolemia with probucol
36. Effects of probucol on homozygous cases of familial hypercholesterolemia
37. Cholestyramine and nicotinic acid in the treatment of familial hypercholesterolemia in the homozygous form
38. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selctive HMG-CoA reductase inhibitor CI-981: comparison with selected HMG-CoA reductase inhibitor
39. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes
40. Lipid lowering activity of atorvastatin and lovastatin in rodent species; triglyceride lowering in rats correlates with efficacy in LDL animal models
41. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholestreol metabolism and lipoprotein composition in the guinea pig
42. Efficacy and safety of new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
43. Monogenic primary hypercholesterolemia in South Africa
44. Lecithin-cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits
45. Mechanism of the production of small dense LDL in hypertriglyceridemia